TrueMark Investments LLC Has $5.06 Million Position in Kenvue Inc. (NYSE:KVUE)

TrueMark Investments LLC increased its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 10.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 211,025 shares of the company's stock after acquiring an additional 20,430 shares during the quarter. Kenvue comprises 1.3% of TrueMark Investments LLC's portfolio, making the stock its 29th biggest holding. TrueMark Investments LLC's holdings in Kenvue were worth $5,060,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. LaFleur & Godfrey LLC boosted its stake in Kenvue by 29.8% in the 4th quarter. LaFleur & Godfrey LLC now owns 81,300 shares of the company's stock valued at $1,736,000 after purchasing an additional 18,650 shares during the period. Atria Wealth Solutions Inc. boosted its stake in Kenvue by 106.9% in the 4th quarter. Atria Wealth Solutions Inc. now owns 18,257 shares of the company's stock valued at $390,000 after purchasing an additional 9,432 shares during the period. Global Retirement Partners LLC boosted its stake in Kenvue by 651.0% in the 4th quarter. Global Retirement Partners LLC now owns 39,365 shares of the company's stock valued at $840,000 after purchasing an additional 34,123 shares during the period. Private Advisor Group LLC boosted its stake in Kenvue by 34.1% in the 4th quarter. Private Advisor Group LLC now owns 50,076 shares of the company's stock valued at $1,069,000 after purchasing an additional 12,729 shares during the period. Finally, Ieq Capital LLC boosted its stake in Kenvue by 20.0% in the 4th quarter. Ieq Capital LLC now owns 12,853 shares of the company's stock valued at $274,000 after purchasing an additional 2,146 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Trading Up 0.1%

Shares of Kenvue stock opened at $21.39 on Monday. The firm has a market capitalization of $41.03 billion, a PE ratio of 38.88, a price-to-earnings-growth ratio of 3.32 and a beta of 0.98. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. The firm's 50 day moving average is $22.99 and its 200 day moving average is $22.40. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.01. The company had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The firm's revenue was down 3.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.28 EPS. Equities research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were given a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, May 14th. This represents a $0.82 annualized dividend and a yield of 3.83%. Kenvue's dividend payout ratio is presently 149.09%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Redburn Atlantic assumed coverage on Kenvue in a research report on Thursday, April 10th. They set a "neutral" rating and a $23.50 target price for the company. Canaccord Genuity Group upped their target price on Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Barclays upped their target price on Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research report on Monday, May 12th. Piper Sandler upped their target price on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research report on Monday, February 24th. Finally, Citigroup reiterated a "neutral" rating on shares of Kenvue in a research report on Friday, June 13th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $25.33.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.